11/5/2026

speaker
Operator
Conference Call Operator

Good afternoon and welcome to the Mankind Corporation 3rd Quarter 2026 Financial Results Earnings Call. As a reminder, this call is being recorded on November 5th, 2026 and will be available for replay on the Mankind Corporation website shortly after this call for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risks factors, please see Form 10Q for the period ended September 30th, 2026, the earnings release, and the slides prepared for this presentation. Joining us today from Mankind are Chief Executive Officer Michael Castagna and Chief Financial Officer Chris Prentiss. I'd now like to turn the call over to Mr. Castagna. Please go ahead, sir.

speaker
Michael Castagna
Chief Executive Officer

Thank you, Operator, and good afternoon, everyone. And thank you for joining us for our third quarter 2026 earnings call. I'll start with our quarter highlights, then provide some business updates, while Chris walks us through our financial results, and I'll provide some closing remarks. Thank you for joining us. Five years ago, we were a company with roughly $75 million in revenue and one commercial product. Since then, we've grown revenue at a compound annual rate of more than 40%, and this year we expect to be close to six times that size. What I'm most proud of is how we've grown. We didn't get there on a single product or a single deal. First, our collaboration with United Therapeutics took off, and Tyveso DPI became a blockbuster built on our DPI technology. and its royalties and manufacturing revenue has funded our transformation. Then we used this foundation to expand our commercial business and today Furosix and Afrezza are leading our growth. That growth is now reaching the bottom line. We expect record revenue in Q4 will drive us to profitability as we close out the year. And none of this reflects our pipeline or external business development opportunities that can drive faster inorganic growth. So today, Mankind isn't a single product store anymore. We're a diversified growth company with four FDA-approved products, no near-term IP cliffs, or a concentrated risk on any one brand or therapeutic area. Today, we have three value engines driving growth. Each one plays a different role. First, we hit the key milestones laid out this year, and our commercial launches are growing nicely. Furosix ReadyFlow is off to an exceptional start with rapid conversion from the own body infuser and new patient growth. And the Afrezza Pediatric Launch is seeing strong early adoption. Second, our license agreement with United Therapeutics provides Mankind with Cash Flow that funds the development and will start to drop to the bottom line in 2027 and beyond. We anticipate $15 million in milestones from the Lenapeg DPI in 2027. Third, our DPI platform provides upside. This is long-term value creation. The Tetanib DPI is our long-targeted approach to IPF treatment, and key clinical evidence investors should look for is the data readout we're anticipating in the first half of 2028. And with our out-licensed programs, Tevesa DPI and Relenopec DPI, give us three potential paths into IPF. Now let me hit the exciting highlights for the quarter. Furosic's ReadyFlow was approved and by late October, roughly 75% of Furosic shipments had moved to ReadyFlow, exceeding our internal expectations by several quarters. The marketing sales team did an amazing job and it tells you physicians and patients were eager for this product. The Afrezza pediatric launch has exceeded all of our internal forecasts, including institutions and healthcare provider adoption, as well as our total prescriptions. Thank you for joining us. Several countries have now approved our new Phase 2 protocol, enabling us to get clinical readout faster. And finally, we closed the $50 million private placement led by Fraser Life Sciences, which funded the $45 million CVR payment triggered by the ReadyFlow approval. This is a strong endorsement of our strategy from a high-quality long-term investor. Now let's step back and look at the first nine months of the year. Total year-to-date revenue was $301 million, up 27% versus last year. Commercial product revenue from Afreza and Furosix more than doubled from $52 million to $112 million, up 116%, and royalties grew 8% to $103 million. The majority of our growth is now coming from products we promote, which will provide long-term sustainable revenue where we can bolt on other BD and pipeline opportunities to drive even faster growth in the coming years. United Therapeutics put up excellent numbers for Tybesa DPI, which returned to growth in the third quarter with $379 million in sales. On the call yesterday, they described stronger underlying demand, more consistent commercial execution, and increased adoption of higher dose cartridges. Importantly, UT also pointed to an improvement in referrals beginning in September with further benefits from its expanded commercial organization expected in the fourth quarter and well into 2027. Our royalties were $37.5 million, up 16% versus Q2. As the sole manufacturer of Taveso DPI, we continue to benefit from both royalties and manufacturing revenue. This recurring cash flow funds our diversified growth strategy that investors will start to see in Q4, as we expect this quarter to be the best quarter in the history of mankind. Now let me turn to business updates starting with 06. Furosix ReadyFlow fundamentally took an administration that used to be measured by number of days in a hospital to seconds at home. This radical shift matters to patients and prescribers and will fundamentally transform how health systems think about managing fluid overload in the coming years. And I'll share with you some new market research we just conducted in a minute. We began shipping ReadyFlow in mid-September and in six weeks, nearly 75% of the prescriptions have already converted to ReadyFlow. The majority of patients starting ReadyFlow are new to brand, and more than 1,600 prescribers have written their first prescription. These are all encouraging signs this early in the launch, and we expect to see faster growth for the balance of the quarter and estimate Q4 sales should match the entire first half of 2027. How big can fluorosis be? Our independent research we just conducted with LAK reinforces the opportunity across nearly every stage of the fluid overload journey. For patients, the value is treatment outside the hospital with easier access and affordable out-of-pocket costs. Thank you so much for joining us. Thank you so much for joining us. And today, with the ReadyFlow approval, along with our incredible team leading us forward and the rapid adoption by prescribers, we are more excited than ever about the opportunity to help transform the management of fluid overload and the growth ahead. Now let me turn to Afrezza. Afrezza generated $19.3 million in net revenue in the third quarter, up about 5% versus third quarter last year. and total prescriptions grew 17% sequentially. Pediatric patients now represent about one in four effective prescriptions and the pediatric launch is now returning the brand to growth. I also want to be candid about our adult business, which is underperformed this year. There are three reasons why this is. First, turnover in our field team slowed activity with some of our key prescribers. Second, several new insulin pumps launched in type 2 diabetes, which created more competition for the same patients. This was compounded by our third, which we can now look back and see, but Fresa is promotionally responsive, as our share of voice in adults was declined about 65% as we diverted our resources across to pediatric launch and nephrology to support Furosix. As we look ahead to 2027, the opportunity to build on that early pediatric demand while re-energizing and focusing on the adult business will allow us to return the brand to growth. The early adoption of the pediatric launch picture is strong. Four months in, Afrez's share of the pediatric mealtime insulin prescriptions is more than double its share in adults. We never reached that share in the adult market and in peas, we got there in a matter of months. Also, average monthly new-to-brand prescriptions for Afrezza are up nearly 80% versus the second quarter. In fact, Q3 alone came close to matching new patient starts for the entire first half. That's the trend we're focused on building upon. Behind that foundation that is in place is more than 2,000 pediatric patients who have been treated since launch with roughly 600 pediatric prescribers, and all 60 of our priority pediatric institutions have now prescribed Afrezza. We continue to see institutions adopt AFRESA and create back-to-school protocols as patients are now starting to return after having early success and creating a flywheel that we hope will continue to drive further growth ahead. With that, I'll now turn it over to Chris to discuss our financial results. Thanks, Mike, and good afternoon, everyone.

speaker
Chris Prentiss
Chief Financial Officer

Third quarter total revenue was $101.9 million, up 24%, from $82.1 million in the third quarter of 2025. The headline this quarter is our continued diversification of our revenues. Commercial product revenue was $45 million, with the addition of Ferosix roughly double the $22.3 million in the prior year quarter, making commercial products our largest source of revenue. At the product level, Ferosix generated $22.4 million in net revenue. ReadyFlow shipments began in mid-September, and September was a record month for both prescribers and prescriptions. As Mike noted, demand shifted to ReadyFlow faster than we expected, and that pace tempered reported revenue in the quarter as patients and prescribers moved to ReadyFlow before the product was available for dispense. Additionally, based on launch inventories available, channel inventory was limited to just days. We estimate the transition reduced third quarter revenue by roughly $3 million. With ReadyFlow now moving through the channel, we believe Ferosix will generate more revenue in the fourth quarter than it did in the entire first half of 2026. This is important as ReadyFlow has a meaningfully lower cost of goods than the on-body infuser, so the faster we convert, the faster that margin improvement flows through to the bottom line. Afreza generated $19.3 million in net revenue, up 5% year over year, with total prescriptions up roughly 17% from the second quarter, driven by the pediatric launch. Because of our pediatric access program, which runs through the end of 2026, prescription growth is running ahead of revenue for now. That said, more than half of pediatric prescriptions are already being reimbursed by insurance and converting the rest to paid coverage is a priority as we head into 2027. Our United Therapeutics revenue streams complement the growing contribution from our commercial portfolio and continued investment in our pipeline. Royalty revenue increased 12% to $37.5 million, driven by growth in Tyveso DPI. Collaboration and services revenue was $19.4 million, compared with $26.5 million in the prior year quarter. As a reminder, UT sets its order quantity on an annual basis. Thus, quarterly fluctuations are a reflection of the timing of deliveries within the year and not a change in anticipated annual order volume. We continue to estimate that collaboration and services revenue for the year will be consistent with the 2025 total. Stepping back to the first nine months of the year, total revenue was $301.4 million, up 27% from $237.0 million in the same period of 2025. Commercial product revenue was $120.9 million, up 90%. Ferocix contributed $60.1 million, driving the growth in commercial revenue. Afreza was in line with the prior year at $51.6 million, but the trend improved after the pediatric launch in June and the brand returned to growth in the third quarter. On the collaboration side, royalties grew 8% to 102.6 million, driven by continued growth in Tyveso DPI and collaboration and services revenue of 77.9 million, which was in line with the prior year. These collaboration revenues have allowed us to build a diversified business. Two years ago, the majority of our revenue came from United Therapeutics. Today, commercial products are a growing share of a larger revenue base with a durable collaboration business underneath it. Turning to the bottom line, gap net loss for the third quarter was $23.2 million compared with net income of $8.0 million in the third quarter of 2025. For the first nine months, GAAP net loss was $58.9 million compared with net income of $21.8 million in the prior year period. In terms of our 2026 results, a significant component of our GAAP loss was non-cash and tied to the SC Pharma acquisition. In the quarter, that included $11.6 million of expense related to the CVR and $5.2 million in amortization of acquired intangible assets. Year to date, those two items totaled $33.3 million. As we've stated previously, 2026 was an investment year. It's not often a company of our size gets the opportunity to invest in two launches as well as reach an important development milestone in our Mankind 201 program. Based on our progress to date in the current quarter, we expect to return to profitability in the fourth quarter on both a gap and a non-gap basis. And based on the product set we have today, we expect to be profitable in 2027 on an annual basis, while continuing to invest in the growth of our commercial products. With that, I'll turn the call back over to Mike.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API